Head-To-Head Analysis: Atrion (ATRI) and Ocular Therapeutix (OCUL)

Atrion (NASDAQ: ATRI) and Ocular Therapeutix (NASDAQ:OCUL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk and institutional ownership.

Volatility & Risk

Atrion has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500. Comparatively, Ocular Therapeutix has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500.

Earnings & Valuation

This table compares Atrion and Ocular Therapeutix’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Atrion $143.49 million 7.52 $27.58 million $18.05 32.29
Ocular Therapeutix $1.89 million 95.67 -$44.70 million ($2.27) -2.15

Atrion has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Atrion, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for Atrion and Ocular Therapeutix, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Atrion 0 0 0 0 N/A
Ocular Therapeutix 0 1 5 0 2.83

Ocular Therapeutix has a consensus target price of $20.67, suggesting a potential upside of 324.37%. Given Ocular Therapeutix’s higher probable upside, analysts plainly believe Ocular Therapeutix is more favorable than Atrion.

Profitability

This table compares Atrion and Ocular Therapeutix’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Atrion 22.98% 18.34% 16.33%
Ocular Therapeutix -3,241.19% -126.31% -81.51%

Dividends

Atrion pays an annual dividend of $4.80 per share and has a dividend yield of 0.8%. Ocular Therapeutix does not pay a dividend. Atrion pays out 26.6% of its earnings in the form of a dividend. Atrion has increased its dividend for 15 consecutive years.

Institutional & Insider Ownership

59.2% of Atrion shares are owned by institutional investors. Comparatively, 37.1% of Ocular Therapeutix shares are owned by institutional investors. 23.1% of Atrion shares are owned by company insiders. Comparatively, 26.1% of Ocular Therapeutix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Atrion beats Ocular Therapeutix on 10 of the 16 factors compared between the two stocks.

About Atrion

Atrion Corporation (Atrion) is engaged in developing and manufacturing products, primarily for medical applications. The Company’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. Its fluid delivery products include valves that promote infection control and needle safety. It has developed a range of valves designed to fill, hold and release controlled amounts of fluids or gasses on demand for use in various intubation, intravenous, catheter and other applications in areas, such as anesthesia and oncology. Its cardiovascular product, MPS2 Myocardial Protection System (MPS2), is the system used in open-heart surgery that delivers fluids and medications, mixes critical drugs and controls temperature, pressure and other variables. The Company manufactures specialized medical devices that disinfect contact lenses. Its other medical and non-medical product lines consist of instrumentation and associated disposables.

About Ocular Therapeutix

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase III clinical development for glaucoma and ocular hypertension. Its earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the treatment of moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor, and, in collaboration with Regeneron an extended release protein-based anti-vascular endothelial growth factor trap.

Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply